Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques

Kristina Abel, Joy Martinez, Yujuan Yue, Simon F. Lacey, Zhongde Wang, Lisa Strelow, Anindya Dasgupta, Zhongqi Li, Kimberli A. Schmidt, Kristie L. Oxford, Basel Assaf, Jeffrey A. Longmate, Don J. Diamond, Peter A. Barry

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

The use of animal models of human cytomegalovirus (HCMV) infection is critical to refine HCMV vaccine candidates. Previous reports have demonstrated that immunization of rhesus monkeys against rhesus cytomegalovirus (RhCMV) can reduce both local and systemic replication of RhCMV following experimental RhCMV challenge. These studies used prime/boost combinations of DNA expression plasmids alone or DNA priming and boosting with either inactivated virion particles or modified vaccinia virus Ankara (MVA) expressing the same antigens. Viral outcomes included reduced RhCMV replication at the site of subcutaneous inoculation and RhCMV viremia following intravenous inoculation. Since shedding of cytomegalovirus from mucosal surfaces is critical for horizontal transmission of the virus, DNA priming/MVA boosting was evaluated for the ability to reduce oral shedding of RhCMV following subcutaneous challenge. Of six rhesus monkeys vaccinated exclusively against RhCMV glycoprotein B (gB), phosphoprotein 65 (pp65), and immediate-early 1 (IE1), half showed viral loads in saliva that were lower than those of control monkeys by 1 to 3 orders of magnitude. Further, there was a strong association of memory pp65 T cell responses postchallenge in animals exhibiting the greatest reduction in oral shedding. These results highlight the fact that a DNA/MVA vaccination regimen can achieve a notable reduction in a critical parameter of viral replication postchallenge. The recently completed clinical trial of a gB subunit vaccine in which the rate of HCMV infection was reduced by 50% in the individuals receiving the vaccine is consistent with the results of this study suggesting that additional immunogens are likely essential for maximum protection in an outbred human population.

Original languageEnglish (US)
Pages (from-to)2878-2890
Number of pages13
JournalJournal of Virology
Volume85
Issue number6
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Macacine herpesvirus 3
Virus Shedding
Cytomegalovirus
viral shedding
Macaca mulatta
Vaccines
vaccines
Human herpesvirus 5
Vaccinia virus
Phosphoproteins
Cytomegalovirus Infections
phosphoproteins
vaccination
DNA
Cytomegalovirus Vaccines
glycoproteins
mouth
Subunit Vaccines
Aptitude
DNA Viruses

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Abel, K., Martinez, J., Yue, Y., Lacey, S. F., Wang, Z., Strelow, L., ... Barry, P. A. (2011). Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. Journal of Virology, 85(6), 2878-2890. https://doi.org/10.1128/JVI.00883-10

Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. / Abel, Kristina; Martinez, Joy; Yue, Yujuan; Lacey, Simon F.; Wang, Zhongde; Strelow, Lisa; Dasgupta, Anindya; Li, Zhongqi; Schmidt, Kimberli A.; Oxford, Kristie L.; Assaf, Basel; Longmate, Jeffrey A.; Diamond, Don J.; Barry, Peter A.

In: Journal of Virology, Vol. 85, No. 6, 03.2011, p. 2878-2890.

Research output: Contribution to journalArticle

Abel, K, Martinez, J, Yue, Y, Lacey, SF, Wang, Z, Strelow, L, Dasgupta, A, Li, Z, Schmidt, KA, Oxford, KL, Assaf, B, Longmate, JA, Diamond, DJ & Barry, PA 2011, 'Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques', Journal of Virology, vol. 85, no. 6, pp. 2878-2890. https://doi.org/10.1128/JVI.00883-10
Abel, Kristina ; Martinez, Joy ; Yue, Yujuan ; Lacey, Simon F. ; Wang, Zhongde ; Strelow, Lisa ; Dasgupta, Anindya ; Li, Zhongqi ; Schmidt, Kimberli A. ; Oxford, Kristie L. ; Assaf, Basel ; Longmate, Jeffrey A. ; Diamond, Don J. ; Barry, Peter A. / Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. In: Journal of Virology. 2011 ; Vol. 85, No. 6. pp. 2878-2890.
@article{52a912872d11470faf4157284db5e15c,
title = "Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques",
abstract = "The use of animal models of human cytomegalovirus (HCMV) infection is critical to refine HCMV vaccine candidates. Previous reports have demonstrated that immunization of rhesus monkeys against rhesus cytomegalovirus (RhCMV) can reduce both local and systemic replication of RhCMV following experimental RhCMV challenge. These studies used prime/boost combinations of DNA expression plasmids alone or DNA priming and boosting with either inactivated virion particles or modified vaccinia virus Ankara (MVA) expressing the same antigens. Viral outcomes included reduced RhCMV replication at the site of subcutaneous inoculation and RhCMV viremia following intravenous inoculation. Since shedding of cytomegalovirus from mucosal surfaces is critical for horizontal transmission of the virus, DNA priming/MVA boosting was evaluated for the ability to reduce oral shedding of RhCMV following subcutaneous challenge. Of six rhesus monkeys vaccinated exclusively against RhCMV glycoprotein B (gB), phosphoprotein 65 (pp65), and immediate-early 1 (IE1), half showed viral loads in saliva that were lower than those of control monkeys by 1 to 3 orders of magnitude. Further, there was a strong association of memory pp65 T cell responses postchallenge in animals exhibiting the greatest reduction in oral shedding. These results highlight the fact that a DNA/MVA vaccination regimen can achieve a notable reduction in a critical parameter of viral replication postchallenge. The recently completed clinical trial of a gB subunit vaccine in which the rate of HCMV infection was reduced by 50{\%} in the individuals receiving the vaccine is consistent with the results of this study suggesting that additional immunogens are likely essential for maximum protection in an outbred human population.",
author = "Kristina Abel and Joy Martinez and Yujuan Yue and Lacey, {Simon F.} and Zhongde Wang and Lisa Strelow and Anindya Dasgupta and Zhongqi Li and Schmidt, {Kimberli A.} and Oxford, {Kristie L.} and Basel Assaf and Longmate, {Jeffrey A.} and Diamond, {Don J.} and Barry, {Peter A.}",
year = "2011",
month = "3",
doi = "10.1128/JVI.00883-10",
language = "English (US)",
volume = "85",
pages = "2878--2890",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques

AU - Abel, Kristina

AU - Martinez, Joy

AU - Yue, Yujuan

AU - Lacey, Simon F.

AU - Wang, Zhongde

AU - Strelow, Lisa

AU - Dasgupta, Anindya

AU - Li, Zhongqi

AU - Schmidt, Kimberli A.

AU - Oxford, Kristie L.

AU - Assaf, Basel

AU - Longmate, Jeffrey A.

AU - Diamond, Don J.

AU - Barry, Peter A.

PY - 2011/3

Y1 - 2011/3

N2 - The use of animal models of human cytomegalovirus (HCMV) infection is critical to refine HCMV vaccine candidates. Previous reports have demonstrated that immunization of rhesus monkeys against rhesus cytomegalovirus (RhCMV) can reduce both local and systemic replication of RhCMV following experimental RhCMV challenge. These studies used prime/boost combinations of DNA expression plasmids alone or DNA priming and boosting with either inactivated virion particles or modified vaccinia virus Ankara (MVA) expressing the same antigens. Viral outcomes included reduced RhCMV replication at the site of subcutaneous inoculation and RhCMV viremia following intravenous inoculation. Since shedding of cytomegalovirus from mucosal surfaces is critical for horizontal transmission of the virus, DNA priming/MVA boosting was evaluated for the ability to reduce oral shedding of RhCMV following subcutaneous challenge. Of six rhesus monkeys vaccinated exclusively against RhCMV glycoprotein B (gB), phosphoprotein 65 (pp65), and immediate-early 1 (IE1), half showed viral loads in saliva that were lower than those of control monkeys by 1 to 3 orders of magnitude. Further, there was a strong association of memory pp65 T cell responses postchallenge in animals exhibiting the greatest reduction in oral shedding. These results highlight the fact that a DNA/MVA vaccination regimen can achieve a notable reduction in a critical parameter of viral replication postchallenge. The recently completed clinical trial of a gB subunit vaccine in which the rate of HCMV infection was reduced by 50% in the individuals receiving the vaccine is consistent with the results of this study suggesting that additional immunogens are likely essential for maximum protection in an outbred human population.

AB - The use of animal models of human cytomegalovirus (HCMV) infection is critical to refine HCMV vaccine candidates. Previous reports have demonstrated that immunization of rhesus monkeys against rhesus cytomegalovirus (RhCMV) can reduce both local and systemic replication of RhCMV following experimental RhCMV challenge. These studies used prime/boost combinations of DNA expression plasmids alone or DNA priming and boosting with either inactivated virion particles or modified vaccinia virus Ankara (MVA) expressing the same antigens. Viral outcomes included reduced RhCMV replication at the site of subcutaneous inoculation and RhCMV viremia following intravenous inoculation. Since shedding of cytomegalovirus from mucosal surfaces is critical for horizontal transmission of the virus, DNA priming/MVA boosting was evaluated for the ability to reduce oral shedding of RhCMV following subcutaneous challenge. Of six rhesus monkeys vaccinated exclusively against RhCMV glycoprotein B (gB), phosphoprotein 65 (pp65), and immediate-early 1 (IE1), half showed viral loads in saliva that were lower than those of control monkeys by 1 to 3 orders of magnitude. Further, there was a strong association of memory pp65 T cell responses postchallenge in animals exhibiting the greatest reduction in oral shedding. These results highlight the fact that a DNA/MVA vaccination regimen can achieve a notable reduction in a critical parameter of viral replication postchallenge. The recently completed clinical trial of a gB subunit vaccine in which the rate of HCMV infection was reduced by 50% in the individuals receiving the vaccine is consistent with the results of this study suggesting that additional immunogens are likely essential for maximum protection in an outbred human population.

UR - http://www.scopus.com/inward/record.url?scp=79952417685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952417685&partnerID=8YFLogxK

U2 - 10.1128/JVI.00883-10

DO - 10.1128/JVI.00883-10

M3 - Article

C2 - 21191005

AN - SCOPUS:79952417685

VL - 85

SP - 2878

EP - 2890

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 6

ER -